SCHEMBL2306038

SCHEMBL2306038

O=C(Nc1ccc(I)cc1F)c1ccc(Cl)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM4 O15151 1/20 0.54
TP53 P04637 1/20 0.54
MDM2 Q00987 1/20 0.54
KCNQ3 O43525 8/20 0.53
KCNQ2 O43526 8/20 0.53
KCNE1 P15382 7/20 0.53
KCNQ1 P51787 7/20 0.53
BACE1 P56817 1/20 0.51
RAB9A P51151 2/20 0.50
KDR P35968 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPC1 O15118 1/20 0.49
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
KDM4E B2RXH2 1/20 0.47
HTT P42858 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063955 0.88 NPC1 (0.62) MDM4TP53MDM2KCNQ3KCNQ2
SCHEMBL2302927 0.83 ALDH1A1 (0.64) MDM4TP53MDM2KCNQ3KCNQ2
SCHEMBL4073255 0.82 MDM4 (0.70) MDM4TP53MDM2KCNQ3KCNQ2
SCHEMBL1233691 0.80 HDAC1 (0.68) MDM4TP53MDM2KCNQ3KCNQ2
SCHEMBL3311781 0.79 LMNA (0.55) MDM4TP53MDM2KCNQ3KCNQ2
SCHEMBL19405833 0.77 KCNQ3 (0.55) MDM4TP53MDM2KCNQ3KCNQ2
SCHEMBL2302330 0.77 KCNQ3 (0.60) MDM4TP53MDM2KCNQ3KCNQ2
SCHEMBL17801687 0.77 GAA (0.74) SMN1; SMN2LMNAPOLBALDH1A1GAA
SCHEMBL1235368 0.77 HDAC1 (0.60) MDM4TP53MDM2KCNQ3KCNQ2
SCHEMBL21462534 0.75 MDM4 (0.57) MDM4TP53MDM2KCNQ3KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 EP disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
CN-102203280-A Diacylglycerol acyltransferase inhibitors VIA PHARMACEUTICALS INC 2011-09-28 CN disclosed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 EP disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 MDM4 4526/4885TP53 4044/4885MDM2 4185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.